Improved detection of breast cancer on FDG-PET cancer screening using breast positioning device

[1]  G. Murphy,et al.  UICC meeting on breast‐cancer screening in pre‐menopausal women in developed countries. Geneva, 29 September‐1 October 1993 , 2007, International journal of cancer.

[2]  Abass Alavi,et al.  Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  M. Ide.  Cancer screening with FDG-PET. , 2006, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[4]  Abass Alavi,et al.  Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  Michael Bader,et al.  Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  S. Yasuda,et al.  PET and cancer screening , 2005, Annals of nuclear medicine.

[7]  M. Ide,et al.  Is whole-body FDG-PET valuable for health screening? , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Liang-Kuang Chen,et al.  Application of PET and PEt/CT imaging for cancer screening. , 2004, Anticancer research.

[9]  Robert Livingston,et al.  Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. , 2004, AJR. American journal of roentgenology.

[10]  Thomas Beyer,et al.  Advantages and limitations of FDG PET in the follow-up of breast cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  P. Mikosch,et al.  Comparison of FDG-PET and dynamic contrast-enhanced MRI in the evaluation of suggestive breast lesions. , 2003, Breast.

[12]  H. Schirrmeister,et al.  Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures , 2001, European Journal of Nuclear Medicine.

[13]  S. Yasuda,et al.  Application of positron emission tomography imaging to cancer screening , 2000, British Journal of Cancer.

[14]  M. Tatsumi,et al.  Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. , 2000, Journal of computer assisted tomography.

[15]  J. Maublant,et al.  Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentre trial , 1998, European Journal of Nuclear Medicine.

[16]  M Schwaiger,et al.  Breast imaging with fluorine-18-FDG PET: quantitative image analysis. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  M Schwaiger,et al.  Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Villanueva-Meyer,et al.  Mammoscintigraphy with technetium-99m-sestamibi in suspected breast cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  I. Mena,et al.  Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  A. Robidoux,et al.  Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  G. Murphy,et al.  UICC meeting on breast‐cancer screening in pre‐menopausal women in developed countries , 1994, Cancer.

[22]  J L Sunshine,et al.  Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. , 1993, Radiology.

[23]  S. Wall,et al.  Breast cancer screening with mammography: overview of Swedish randomised trials , 1993, The Lancet.

[24]  L. Tabár.  Control of breast cancer through screening mammography. , 1990, Radiology.

[25]  G. Antoch,et al.  Can PET/CT replace separate diagnostic CT for cancer imaging? Optimizing CT protocols for imaging cancers of the chest and abdomen. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[27]  J. Czernin.  FDG-PET in breast cancer: a different view of its clinical usefulness. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.